1. Characteristics of ongoing studies.
| Study ID | Title | Intervention | Comparator | Other study interventions | Planned number of participants | Setting | Planned completion date | Link |
| ChiCTR2000030055 | Multicentre study for the treatment of Dipyridamole with novel coronavirus pneumonia | Dipyridamole | Standard care | None | 460 | Hospital | NR | covid-19.cochrane.org/studies/crs-13247467 |
| IRCT20180205038626N7 | The Investigation of the Effectiveness of ASA Usage on the Incidence of Cardiovascular Events in Patients with Corona Virus (COVID‐19) A Clinical Trial Study | Acetylsalicylic acid | Placebo | None | 36 | Hospital | NR | en.irct.ir/trial/52374 |
| NCT04703608 | Prevention and Treatment for COVID ‐19 (Severe Acute Respiratory Syndrome Coronavirus 2 SARS‐CoV‐2) Associated Severe Pneumonia in the Gambia | Acetylsalicylic acid | Placebo | Ivermectin | 1200 | Hospital and private household | March 2022 | clinicaltrials.gov/ct2/show/record/NCT04703608?cond=NCT%3A+04703608&draw=2&rank=1 |
| NCT04808895 | Acetylsalicylic Acid in the Prevention of Severe SARS‐CoV2 Pneumonia in Hospitalised Patients With COVID‐19 | Acetylsalicylic acid | Placebo | None | 204 | NR | July 2021 | clinicaltrials.gov/ct2/show/record/NCT04808895?cond=NCT%3A+04808895&draw=2&rank=1 |
| CTRI/2020/08/027503 | Low Dose Aspirin in Moderate to Severe SARS‐ CoV‐2 Infected Patients: A Pilot Randomized Controlled Trial | Acetylsalicylic acid | Standard care | None | 60 | Hospital | NR | www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=44980&EncHid=&modid=&compid=%27,%2744980det%27 |
| NCT04768179 | Safety and Efficacy of Low Dose Aspirin / Ivermectin Combination Therapy for Treatment of Covid‐19 Patients | Acetylsalicylic acid | Standard care | Ivermectin | 490 | Hospital | June 2021 | clinicaltrials.gov/ct2/show/NCT04768179?cond=NCT04768179&draw=1&rank=1 |
| NCT04363840 | The LEAD COVID‐19 Trial: Low‐risk, Early Aspirin and Vitamin D to Reduce COVID‐19 Hospitalizations | Acetylsalicylic acid | Observation | Vitamin D | 1080 | Hospital | December 2020 | clinicaltrials.gov/ct2/show/NCT04363840?cond=04363840&draw=2&rank=1 |
| NCT04445623 | Prasugrel in Severe COVID‐19 Pneumonia | Prasugrel hydrochloride | Placebo | None | 128 | Hospital | January 2021 | clinicaltrials.gov/ct2/show/NCT04445623?cond=NCT%3A+04445623&draw=1&rank=1 |
| NCT04365309 | Protective Effect of Aspirin on COVID‐19 Patients | Acetylsalicylic acid | Standard care | None | 128 | Hospital | June 2020 | clinicaltrials.gov/ct2/show/NCT04365309?cond=NCT%3A+04365309&draw=2&rank=1 |
| NCT05073718 | Acetylsalicylic Acid in COVID‐19 (ASA‐SARS) | Acetylsalicylic acid | Placebo | Prophylactic doses of LMWH | 398 | NR | October 2023 | https://clinicaltrials.gov/ct2/show/NCT05073718 |
| CTRI/2021/03/032059 | Investigator Initiated Study to Evaluate the Effect of Marketed Colchicine 0.5mg Given Along Marketed Asprin 75mg with SOC and Marketed Aspirin 75mg with SOC on COVID 19 patients | Acetylsalicylic acid | Colchicine | None | 63 | Outpatient | NR | www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=53115&EncHid=&modid=&compid=%27,%2753115det%27 |
| NCT04937088 | Outpatient Liquid Aspirin (OLA) (OLA COVID) | Acetylsalicylic acid | Placebo | None | 200 | Outpatient | June 2022 | clinicaltrials.gov/ct2/show/NCT04937088 |
| CTRI/2021/06/034254 | Clinical trial of APMV2020 in Covid 19 Subjects | Acetylsalicylic acid | Multivitamin and multimineral tablet | Promethazine hydrochloride | 60 | Outpatient | NR | www.cochranelibrary.com/central/doi/10.1002/central/CN-02327762/full |
| Sharma 2021 | A Randomized Open‐Label Trial to Evaluate the Efficacy and Safety of Triple Therapy with Aspirin, Atorvastatin, and Nicorandil in Hospitalised Patients with SARS Cov‐2 Infection | Acetylsalicylic acid | Standard care | Atorvastatin, nicorandil | 396 | Hospital | NR | trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05361-y |
NR: not reported